Moderna, Inc. (MRNA)
Moderna describes itself as a pioneer and leader in mRNA medicine, using its mRNA platform to develop medicines to treat and prevent diseases.
| Ticker | MRNA |
|---|
| Company | Moderna, Inc. |
|---|
| Exchange | Nasdaq |
|---|
| Headquarters | CAMBRIDGE, MA |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$788,000,000 |
|---|
| Cost of Goods and Services Sold | $93,000,000 |
|---|
| Earnings Per Share, Basic | -2 USD/shares |
|---|
| Earnings Per Share, Diluted | -2 USD/shares |
|---|
| Gross Profit (derived) | $52,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | -$767,000,000 |
|---|
| Income Tax Expense (Benefit) | $15,000,000 |
|---|
| Investment Income, Interest | $67,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | -$782,000,000 |
|---|
| Operating Income (Loss) | -$815,000,000 |
|---|
| Other Nonoperating Income (Expense) | -$19,000,000 |
|---|
| Research and Development Expense | $651,000,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $145,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $224,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 398,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 398,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro